@article{d69481bfb74c46bc999fd38525781363,
title = "NCCN guidelines{\textregistered} Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines",
abstract = "These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.",
author = "Ettinger, {David S.} and Wood, {Douglas E.} and Wallace Akerley and Bazhenova, {Lyudmila A.} and Hossein Borghaei and Camidge, {David Ross} and Cheney, {Richard T.} and Chirieac, {Lucian R.} and D'Amico, {Thomas A.} and Dilling, {Thomas J.} and {Chris Dobelbower}, M. and Ramaswamy Govindan and Mark Hennon and Leora Horn and Jahan, {Thierry M.} and Ritsuko Komaki and Lackner, {Rudy P.} and Michael Lanuti and Rogerio Lilenbaum and Jules Lin and Loo, {Billy W.} and Renato Martins and Otterson, {Gregory A.} and Patel, {Jyoti D.} and Pisters, {Katherine M.} and Karen Reckamp and Riely, {Gregory J.} and Schild, {Steven E.} and Shapiro, {Theresa A.} and Neelesh Sharma and James Stevenson and Swanson, {Scott J.} and Kurt Tauer and Yang, {Stephen C.} and Kristina Gregory and Miranda Hughes",
year = "2016",
month = mar,
day = "1",
doi = "10.6004/jnccn.2016.0031",
language = "English (US)",
volume = "14",
pages = "255--264",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "3",
}
